Drugs / NU-0129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03020017 | May 2017 → Sep 2018 | gliosarcoma | Northwestern University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NU-0129 | “A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients” NCT03020017 ↗ |
| Modality | Oligonucleotide (other) | “The SNA consists of nucleic acids arranged on the surface of a small spherical gold nanoparticle.” NCT03020017 ↗ |
| Route | Intravenous | “Patients receive NU-0129 intravenously (IV) over 20-50 minutes” NCT03020017 ↗ |
| Target | BCL2L12 | “Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12” NCT03020017 ↗ |